A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Alisertib (Primary) ; Paclitaxel
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 30 Mar 2017 Planned End Date changed from 1 Jun 2016 to 7 Aug 2017.
    • 30 Mar 2017 Planned primary completion date changed from 1 Mar 2016 to 7 Aug 2017.
    • 11 Oct 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top